

RISK COMMITTEE TERMS OF REFERENCE

THE BRITISH UNITED PROVIDENT ASSOCIATION LIMITED

RISK COMMITTEE

Terms of Reference

1. Constitution and Role

The Committee's current Terms of Reference were reviewed and adopted by a resolution of the Board on 10 December 2025.

These Terms of Reference set out the authorities and responsibilities delegated to the Committee by the Board.

The purpose of the Committee is to provide oversight of the principal and emerging risks for the Group and its risk management systems.

2. Membership and Secretary

2.1 Composition

The Committee shall comprise at least three members, all of whom shall be Independent Non-Executive Directors, and include the Chair of the Audit Committee and, if possible, a member of the Remuneration Committee. The Chair of the Board shall not be a member of the Committee.

The Committee Chair and its members shall be appointed by the Board, on the recommendation of its Nomination & Governance Committee.

2.2 Chair

In the absence of the Committee Chair, the members present at any meeting of the Committee shall elect one of their number to chair the meeting.

2.3 Disclosure of interests

Each member of the Committee shall disclose to the Committee:

- (i) the nature of any direct or indirect, actual or potential, interest in any proposed transaction or arrangement with the Company; and
- (ii) any direct or indirect, actual or potential, conflict with the interests of the Company arising in relation to any business of the Committee.

Any such member shall abstain from voting on resolutions that relate to such an interest or conflict. They shall also recuse themselves from all discussions on such matter, unless otherwise authorised by the Board.

RISK COMMITTEE TERMS OF REFERENCE

2.4 **Secretary**

The Group Company Secretary or their nominee shall be Secretary to the Committee.

3. **Meetings**

3.1 **Frequency and duration**

At least four meetings shall be held annually, with any additional meetings to be agreed by the Committee Chair. Meetings shall be of suitable duration to allow full discussion of the matters required.

3.2 **Quorum**

The quorum for meetings of the Committee shall be two members present throughout the meeting, in person or by electronic means.

3.3 **Notice**

Notice of each meeting confirming the date, time and venue shall be circulated by the Secretary to all members of the Committee and to other attendees (if appropriate) as far in advance as possible.

3.4 **Meeting papers**

Papers for each meeting shall be circulated by the Secretary to all members of the Committee and to other attendees (if appropriate) at least five working days before a meeting.

3.5 **Attendance**

Only the Chair and members of the Committee are entitled to be present at meetings of the Committee. The Board Chair may attend at their discretion.

The Group Chief Executive Officer, Group Chief Financial Officer, Group Chief Risk Officer, Group Chief Audit Officer, and the external auditor will be invited to attend meetings on a regular basis.

The Committee may invite other person(s) to attend all or part of any meeting when it considers appropriate.

3.6 **Minutes**

The Secretary shall produce minutes of each Committee meeting within ten working days of the meeting and circulate them to the Committee Chair for review. Minutes should be presented to the following meeting for Committee review and approval as a true and accurate record of the meeting.

4. Duties and responsibilities

The Committee shall:

4.1 Risk Management

(i) **Risk Appetite, Tolerance and Risk**

Annually review Bupa's risk appetite, tolerance and strategy, considering the current and prospective macroeconomic, financial, clinical and regulatory environment and its principal and emerging risks, and:

- (a) evaluate and advise the Board on whether Bupa's overall risk strategy, appetite and tolerance align to Bupa's stated purpose and values and the principal and emerging risks it is willing to take in order to achieve its long-term strategic objectives;
- (b) consider Bupa's capability to identify and manage new types of risks; and
- (c) review, and provide an opinion to the Board on, any matters and activities that are, or are likely to take Bupa, outside its risk appetite.

(ii) **Risk Management**

Oversee and seek suitable assurance, and advise the Board, regarding:

- (a) the current risk exposures and profile of the Company, including its principal risks, emerging risks, future risk strategy and risk culture, in respect of the business model, future performance, operations, business continuity, reputation and solvency and capital risks.
- (b) any emerging and new risks, or material changes to current risks, related to sustainability and environmental, social and governance matters (ESG).
- (c) the adequacy and effectiveness of the Company's processes and procedures with the risk management and internal control framework, including the design, implementation, and effectiveness of Bupa's Risk Appetite Framework and Risk Management Framework.
- (d) the ability of the risk management and internal control framework to identify the principal and emerging risks facing Bupa and enable a robust assessment of the principal risks.
- (e) compliance with relevant legal and regulatory obligations.
- (f) the effectiveness of the first-line's processes for monitoring and reviewing the effectiveness of the Company's risk management and internal control framework and ensuring corrective action is taken when necessary.

RISK COMMITTEE TERMS OF REFERENCE

- (iii) At least annually review the Company's Risk Appetite Framework and Risk Management Framework and recommend to the Board for approval.

- (iv) **Enterprise Risk Policies**

Oversee the suite of enterprise risk policies and approve, or recommend to the Board for approval, any changes to these policies.

4.2 Risk Monitoring

- (i) **Risk Profile**

Oversee Bupa's current principal and emerging risk exposures and any impact to its strategy and objectives, the continued viability of its business model, solvency and liquidity.

- (ii) **Risk Performance and Reporting**

Assess the adequacy and effectiveness of Bupa's processes, procedures and risk reporting to identify and manage principal and emerging risks including, but not limited to, financial, regulatory, clinical and operational risks.

- (iii) **Incident Oversight**

Review reports, and any lessons learned, on any material incidents, breaches in risk appetite limits, or breakdowns in operational controls (including IT infrastructure) and assess the adequacy of remedial actions.

- (iv) **Regulation and Compliance**

Consider and review:

- (a) compliance with applicable laws and regulation;
- (b) relationships with regulatory authorities in relevant jurisdictions and developments in the regulatory environment; and
- (c) the annual regulatory compliance programme.

4.3 Stress Testing

- (i) Satisfy itself that Bupa's risk appetite, business plan and any capital implications are reviewed and assessed by management through appropriate stress and scenario testing and that any mitigating actions are identified.

- (ii) Review and assess the robustness of the stress and scenario testing plan.

- (iii) Review the outcomes of the annual stress and scenario testing programme.

RISK COMMITTEE TERMS OF REFERENCE

4.4 Risk Capital

- (i) Review management's methodology and assumptions for determining the economic and regulatory capital requirements, and that the assumptions and calibrations used reflect Bupa's forward-looking risk profile.
- (ii) Review, and recommend to the Board for approval, the Group Own Risk and Solvency Assessment report.

4.5 Strategic Risks

Review and advise the Board on any potential risk considerations in respect of any of the following, prior to their occurrence:

- (i) commencing (including by way of acquisition):
 - (a) any new business activities or offering of new services or products not currently offered anywhere else in the Group; or
 - (b) any business activity, service or product in a new country or territory;

Unless:

- a review of the risks of operating the relevant activity or offering the service/product or doing business in that country or territory was undertaken by the Committee within the previous three years, *and*
 - there have been no material changes in the risk profile or (business, legal or regulatory) environment during that three-year period.
- (ii) changes to any existing business activities, services or products which could create risk(s) that the Group is not currently exposed to or would otherwise materially change the Group's risk profile.
 - (iii) undertaking material offshoring operations in new countries.
 - (iv) entering into material (over £200m) mergers and acquisitions, joint ventures and strategic partnerships, or increasing exposure above this threshold in respect of existing arrangements.
 - (v) any decision to cease to operate and/or divest all or any material (£100m or more) part of the Group's business or activities.
 - (vi) significant changes to financial risk mitigation strategies.
 - (vii) any other material changes in strategy, or any circumstances referred by the Group Chief Risk Officer to the Committee for consideration.

4.6 Group Chief Risk Officer and Risk Function

- (i) Approve the appointment and removal of the Group Chief Risk Officer and monitor their effectiveness and independence.
- (ii) Ensure the Group Chief Risk Officer has direct access to the Committee Chair and members, and the Board Chair, and that they have direct access to the Group Chief Risk Officer.

RISK COMMITTEE TERMS OF REFERENCE

- (iii) At least once a year, and at any other times as the Committee shall see fit, meet separately with the Group Chief Risk Officer without management present.
- (iv) Review the Risk Function's independence of management, and the adequacy of its resources, its remit, performance and effectiveness, including its interactions with the first- and third-line.

4.7 **Committee performance review**

At least once a year, review its own performance and composition to ensure that it is operating at maximum effectiveness and recommend any changes it considers necessary to the Board for approval.

4.8 **Terms of Reference**

Annually review the Terms of Reference of the Committee, and the Committee's compliance with them, to ensure they remain appropriate and fit for purpose and recommend any changes considered necessary or desirable to the Board for approval.

4.9 **Liaison with other Committees and the Board**

Liaise as necessary with the Board and other Board Committees and provide input to:

- (i) the Remuneration Committee to ensure that risk is properly considered in setting the overall remuneration policy and that the remuneration arrangements of the Executive Directors and Senior Executives promote ethical behaviour and align with Bupa's risk appetite and conduct expectations. Provide advice on any risk weightings to be applied to performance objectives to the extent applicable and make any recommendations on any malus and clawback provisions.
- (ii) the Board Audit Committee on risk-related matters and disclosures, and the Company's annual Board declaration on its review of the effectiveness of the Company's risk management and internal control framework, including in the Annual Report.

Where there is a perceived overlap of responsibilities between the Committee and another committee of the Board, the respective Committee Chairs shall have discretion to agree the most appropriate committee to fulfil any obligation. Notwithstanding paragraph 6.3, an obligation under these Terms of Reference, or of another committee of the Board, will be deemed by the Board to have been fulfilled provided it is dealt with by any Board Committee or by the Board itself.

RISK COMMITTEE TERMS OF REFERENCE

4.10 **Liaison with Subsidiary Company Risk Committees**

Work and liaise as necessary with major subsidiary company risk committees and, to the extent appropriate, any advisory committee or similar body with non-executive members which has been established to oversee the operations of subsidiaries.

4.11 **Other matters**

Consider any other matters referred to the Committee by the Board.

5. **Reporting Responsibilities**

5.1 **The Board**

The Committee Chair shall report to the Board on the proceedings of each Committee meeting and all matters within its duties and responsibilities and make any recommendations it considers appropriate on any area within its remit where action or improvement is needed.

5.2 **Annual Report and accounts**

Review and endorse to the Board Audit Committee, for inclusion in the Company's Annual Report:

- (i) the content of the Committee's report describing its activities; and
- (ii) in conjunction with the Board Audit Committee, any risk-related disclosures and statements including, but not limited to, the narrative on, and effectiveness of: identification and mitigation of the principal and emerging risks to Bupa, the risk management and internal control framework, and Bupa's risk appetite, tolerance and strategy.

5.3 **AGM**

The Chair of the Committee shall attend the Company's Annual General Meeting and be available to respond to any questions on the Committee's activities and areas of responsibility.

6. **Authorities**

6.1 **Resources and support**

The Committee shall be provided with sufficient resources to undertake its duties, including appropriate and timely training as required, and have access to the services of the Secretary and the Group Chief Risk Officer on all Committee matters.

The Committee is authorised to seek any information it requires from any Group employee to perform its duties and will advise the Group Chief Executive Officer if it has exercised this authority to seek information (other than routine information) from any employee, setting out the information required and the circumstances underlying the request.

RISK COMMITTEE TERMS OF REFERENCE

6.2 **Investigation and advice**

The Committee is authorised by the Board to investigate any activity within its Terms of Reference and to intervene if the Committee considers it appropriate and if the Board instructs it to do so. The Committee is also authorised to obtain independent legal or other professional advice on any matter within its Terms of Reference, at the Company's expense, as it considers this necessary. The Committee shall consult with the Board Chair before any fees are agreed.

6.3 **Delegation**

The Committee may delegate any actions in support of its function to a competent person, providing the terms of the delegation are documented in the Committee's records, but it may not delegate its duties and responsibilities relating to the oversight of the Risk and Compliance Function nor its accountability for its duties and responsibilities.

7. **Definitions**

Board means the Board of Directors of the Company.

Bupa/Company means The British United Provident Association Limited.

Group means the Company and its subsidiary companies.

Committee means the Risk Committee of the Board.

Directors means Directors of the Company.

Independent Non-Executive Directors means Directors who have been appointed to the Board of the Company as a Non-Executive Director and are deemed independent of the Company in accordance with the Code.